171 reports of this reaction
4.5% of all AMPHETAMINE SULFATE reports
#3 most reported adverse reaction
COMPLETED SUICIDE is the #3 most commonly reported adverse reaction for AMPHETAMINE SULFATE, manufactured by Azurity Pharmaceuticals, Inc.. There are 171 FDA adverse event reports linking AMPHETAMINE SULFATE to COMPLETED SUICIDE. This represents approximately 4.5% of all 3,842 adverse event reports for this drug.
Patients taking AMPHETAMINE SULFATE who experience completed suicide should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMPLETED SUICIDE is moderately reported among AMPHETAMINE SULFATE users, representing a notable but not dominant share of adverse events.
In addition to completed suicide, the following adverse reactions have been reported for AMPHETAMINE SULFATE:
The following drugs have also been linked to completed suicide in FDA adverse event reports:
COMPLETED SUICIDE has been reported as an adverse event in 171 FDA reports for AMPHETAMINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMPLETED SUICIDE accounts for approximately 4.5% of all adverse event reports for AMPHETAMINE SULFATE, making it one of the most commonly reported side effect.
If you experience completed suicide while taking AMPHETAMINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.